Assessment of Serum Vitamin $\text{B}_12$ and Folate Levels and Macrocytosis in Patients with Type 2 Diabetes Mellitus on Metformin Attending Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: A Cross-Sectional Study

Wondwosen Wale Tesega 1
Solomon Genet 2
Gnanasekeran Netasan 2
Getahun Tarekem 2
Fitsum Girma 3
Dinkinesh Chalchisa 3
Yohannes Belay 3
Zeleke Geto 4
Tadesse Asmamaw Dejenie 5

1Department of Biomedical Sciences, School of Medicine, College of Health Sciences, Arambinch University, Arba Minch, Ethiopia; 2Department of Medical Biochemistry, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia; 3National Reference Laboratory for Immunohematology, Ethiopian Public Health Institute, Addis Ababa, Ethiopia; 4Department of Biomedical Science, College of Medicine and Health Science, Wollo University, Dessie, Ethiopia; 5Department of Biochemistry, School of Medicine, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia

Background: Metformin is the first-line drug in the treatment of type 2 diabetes mellitus. Monitoring vitamin $\text{B}_12$ deficiency associated with long-term and high-dose therapy is not a common practice in many clinical settings in Ethiopia.

Objective: The study aimed to measure levels of serum vitamin $\text{B}_12$ and folate and to assess the macrocytic status of type 2 diabetes mellitus patients on metformin.

Method: A cross-sectional study was conducted on 80 type 2 diabetes mellitus patients who had been on metformin for 5 months or more at the diabetic clinic of Tikur Anbessa Specialized Teaching Hospital. Serum vitamin $\text{B}_12$ and folate levels were quantified by chemiluminescent immunoassays. Mean corpuscular volume was determined by complete blood count. Differences in vitamin $\text{B}_12$ and folate levels and mean corpuscular volume between different groups were assessed using Kruskal–Wallis H and Mann–Whitney U tests.

Results: Vitamin $\text{B}_12$ and folate deficiency were documented in 5% and 23.8% of participants, respectively, and 6.2% of patients were macrocytic. Levels of vitamin $\text{B}_12$ and folate in patients who had been on metformin $>1,500$ mg/day $\geq$ 4 years were significantly lower those who had been on metformin 1,000–1,500 mg/day and $<1,000$ mg/day $<4$ years, respectively.

Conclusion: Low serum vitamin $\text{B}_12$ and folate levels and macrocytosis were found to be associated with prolonged metformin treatment.

Keywords: macrocytosis, metformin, type 2 diabetes mellitus, vitamin $\text{B}_12$, folate

Background:
Metformin has been used widely in the treatment of type 2 diabetes for decades. 1 2 The exact mechanism of metformin action has only been partially explored and remains controversial. However, it has been found that the glucose-lowering effect of metformin is mainly due to the inhibition of hepatic glucose output.

Various guidelines advocate the use of metformin as the first-line glucose-lowering agent concurrently with lifestyle-modification approaches if there are no contraindications like renal and hepatic dysfunction. 3, 4, 4 For example, the American Diabetes Association and American Association of Clinical Endocrinologists recommend the use of metformin as first-line treatment for type 2 diabetes mellitus and prediabetes to prevent progression of the disease. It has been
reported that metformin is a pharmacological cause of vitamin B deficiencies in patients with type 2 diabetes mellitus which leads to long-term deleterious neurological and hematological effects.5–7

Vitamin B12 is a water-soluble vitamin that plays a fundamental role in DNA synthesis, optimal hemopoiesis, and neurological function. In the human body, vitamin B12 is converted enzymatically into its two coenzyme forms, methylcobalamin and adenosylcobalamin.8–10 Through its active forms, vitamin B12 exerts its physiological effects through mediating important enzymatic pathways that help keep the body’s nerve and blood cells healthy and helps to make DNA, the genetic material in all cells. The clinical picture of vitamin B12 deficiency is hence predominantly of features of hematological and neurocognitive dysfunction.8

In the mitochondria, for example, propionyl-CoA is enzymatically carboxylated to methylmalonyl-CoA, which is then reversibly isomerized to succinyl-CoA by the B12-dependent enzyme methylmalonyl-CoA mutase. As such, deficiency in vitamin B12 blocks the production of succinyl-CoA and leads to elevated methylmalonic acid, which induces neuron destabilization and consequential neurological deficits.11,12 In the cytoplasm, the methylation of homocysteine to produce methionine uses 5-methyltetrahydrofolate as the methyl donor in a reaction catalyzed by methionine synthase that requires methylcobalamin.10,12 Therefore, vitamin B12 deficiency leads to a condition known as folate trap (functional folate deficiency), where free folate is trapped in the form of methyltetrahydrofolate. Therefore, deficiency in any form of vitamin B12 and folate ultimately affect methionine metabolism to the point where homocysteine can no longer remethylate back to methionine, causing hyperhomocysteinemia.13,14

Many studies have reported that higher doses and prolonged duration of metformin treatment induce vitamin B12 deficiency and consequential complications in type 2 diabetes mellitus patients.5,7,15 This effect is most often seen after the patient has received long-term treatment (ie, ≥6 months) and high doses (ie, >1 g/day) of metformin.7,16

Different proposed mechanisms explain metformin-induced vitamin B12 deficiency among patients with type 2 diabetes mellitus: alterations in small-bowel motility activating bacterial overgrowth, competitive inhibition or inactivation of vitamin B12 absorption, alterations in intrinsic factor (IF) levels, and interaction with the cubulin endocytic receptor.6 Metformin has also been shown to prevent calcium-dependent absorption of the vitamin B12–IF complex at the terminal ileum.17

Even though metformin is a cornerstone in the treatment of type 2 diabetes, many reports and the package insert of metformin advise patients using high doses for a long time to have routine serum vitamin B12 measurements done every 2–3 years besides the hematological assessments recommended to be done on annual basis.18 However, screening type 2 diabetes mellitus patients using high doses for a long time to monitor metformin’s side effects like vitamin B12 deficiency is not a common clinical practice in many clinical settings in Ethiopia. Therefore, this study aimed to measure levels of serum vitamin B12 and folate and assess the macrocytic status of type 2 diabetes mellitus patients on metformin.

Methods
Between October and December 2019, a total of 80 patients with type 2 diabetes mellitus who fulfilled the American Diabetes Association criteria (reported of the expert committee on the diagnosis and classification of diabetes mellitus, 1997), aged 35 to 79 years and who had been on metformin for 5 months and above, were recruited for this cross-sectional study using a convenient sampling method. All patients were from the Diabetic Clinic of Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia.

Exclusion Criteria
Patients with thyroid disease, liver disease, pernicious anemia, active cancer, end-stage renal disease, chronic pancreatitis, *Helicobacter pylori* infection, or HIV, having undergone gastrectomy or ileal resection, documented diagnosed reason for vitamin B12 malabsorption (alcoholism, atrophic gastritis, celiac disease, Crohn’s disease, gastric banding, or bypass), those on oral/intramuscular vitamin B12 supplements, H2-receptor blockers, proton-pump inhibitors, methotrexate, or chloramphenicol, and vegetarians, pregnant women, alcoholics, and smokers were excluded.

Ethics Approval and Informed Consent
The study adhered to Declaration of Helsinki principles. The study protocol was approved by Addis Ababa University Biochemistry Department Ethics and Research Committee (DRERC). Ethics approval (SOM/BCHM/02/2012) was obtained from the departmental research and ethics review committee of the Department of Medical
Biochemistry and College of Health Sciences Institutional Review Board (DRERC). Informed consent was obtained from participants before sample collection. Confidentiality and privacy were assured.

Data and Blood Collection
Sociodemographic, clinical, and therapeutic data related to type 2 diabetes mellitus were collected from participants’ medical history charts and interviews using an Amharic-language structured questionnaire administered by experienced nurses. After subjects had been fasted overnight, 6 mL venous blood was collected from each participant and dispensed into blood collecting tubes with serum separator and EDTA (4 mL for serum separation and 2 mL for complete blood counts). The 4 mL blood samples were allowed to retract and were then centrifuged at 3,000 rpm for 10 minutes to obtain serum samples that were kept at −20°C until analysis for vitamin B₁₂ and folate levels. Complete blood countswere done immediately after collection. Laboratory testing was done at the National References Laboratory for Clinical Chemistry, Ethiopian Public Health Institute.

Determination of Serum Vitamin B₁₂, Folate, and MCV
Biochemical tests for serum vitamin B₁₂ and folate were analyzed and determined with a Cobas 6000 immunoassay analyzer. A UniCelDxH 800 analyzer (Beckman Coulter) was used for hematology testing to determine mean corpuscular volume (MCV). Vitamin B₁₂ deficiency was defined as a serum concentration <197 pg/mL and folate deficiency as serum concentration <4.6 ng/mL. Macrocytosis was defined as MCV <96 fl.

Statistical Analysis
After checking the distribution of vitamin B₁₂, folate, MCV, and other variables for normality using histograms, Mann–Whitney U and Kruskal–Wallis H tests for abnormally distributed data, were used to determine differences in medians (vitamin B₁₂, folate, and MCV). Independent t-tests and one-way ANOVA with Welch tests for normally distributed data were used to determine differences in means of age and BMI. Data with normal distribution are presented as means ± SD, while data with abnormal distribution are presented as medians (IQRs). Spearman’s correlation coefficient was used to measure relationships among variables. P<0.05 was considered statistically significant. SPSS 25 was used to perform all analyses.

Results
Mean participant age was 56.35±10.60 years, of whom 64 (80%) were above the aged >56 years, 57.5% female, and 93.8% resided in an urban setting. Mean daily dose of metformin was 1,200±644.35 mg, with 4 (1–20) years the median duration of metformin intake. There were 43.8% and 28.7% of patients using insulin and glibenclamide, respectively, in addition to metformin. Vitamin B₁₂- and folate-deficient patients numbered four (5%) and 19 (23.8%), respectively, while the other five (6.2%) patients had macrocytosis (Table 1).

In sum, 43 and 16 participants were taking metformin doses <1,000 mg and 1,000–1,500 mg, respectively, but none had developed vitamin B₁₂ deficiency. However, of the 21 who used metformin >1,500 mg, vitamin B₁₂ deficiency was observed in four. This accounted for 5% of 80 participants (Figure 1).

As depicted in Figure 2, although there were cases of folate deficiency in patients taking metformin <1,000 mg,

<table>
<thead>
<tr>
<th>Table 1 Demographic and Clinical Characteristics of Participants (n=80)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Female, n (%)</strong></td>
</tr>
<tr>
<td><strong>Age (years), mean ± SD</strong></td>
</tr>
<tr>
<td><strong>Urban-dwelling, n (%)</strong></td>
</tr>
<tr>
<td><strong>Duration of type 2 diabetes mellitus (years), median (IQR)</strong></td>
</tr>
<tr>
<td><strong>Duration of metformin treatment (years), median (IQR)</strong></td>
</tr>
<tr>
<td><strong>Daily dose of metformin (mg), mean ± SD</strong></td>
</tr>
<tr>
<td><strong>Use of insulin, n (%)</strong></td>
</tr>
<tr>
<td><strong>Use of glibenclamide, n (%)</strong></td>
</tr>
<tr>
<td><strong>Use of antihypertensives, n (%)</strong></td>
</tr>
<tr>
<td><strong>Use of statins, n (%)</strong></td>
</tr>
<tr>
<td><strong>Vitamin B₁₂ levels, n (%)</strong></td>
</tr>
<tr>
<td>&lt;197 pg/mL</td>
</tr>
<tr>
<td>≥197 pg/mL</td>
</tr>
<tr>
<td><strong>Folate levels, n (%)</strong></td>
</tr>
<tr>
<td>&lt;4.6 ng/mL</td>
</tr>
<tr>
<td>≥4.6 ng/mL</td>
</tr>
<tr>
<td><strong>MCV, n (%)</strong></td>
</tr>
<tr>
<td>80–96 fl</td>
</tr>
<tr>
<td>&gt;96 fl</td>
</tr>
</tbody>
</table>

**Abbreviation:** MCV, mean corpuscular volume.
and 1,000–1,500 mg per day, the highest percentage of folate deficiency was observed in patients on metformin >1,500 mg per day. As the dose increased, the percentage of patients with serum folate levels <4.6 ng/mL increased as well (Figure 2).

Based on metformin intake, patients were divided into two groups: <4 years’ intake and ≥4 years. Four patients who were found to be vitamin B₁₂-deficient had been taking metformin ≥4 years. However, no patients who had been on metformin <4 years experienced vitamin B₁₂ deficiency. Similarly, though there were cases of folate deficiency in patients who had taken metformin <4 years, higher (34.3%) folate deficiency was observed in patients who had been taking metformin ≥4 years (Table 2).

**Note: Data expressed as n (%)**

As shown in Table 3, patients were divided into 3 groups based on daily metformin dose. The median level of vitamin B₁₂ in patients on >1,500 mg/day was significantly lower (P<0.001) than patients on 1,000–1,500 mg/day and <1,000 mg/day. Those on <1,000 mg/day had the highest median B₁₂. Similarly, median serum folate of patients on >1,500 mg/day was significantly lower than patients on
1,000–1,500 mg/day and <1,000 mg/day \( (P=0.002) \). Differences in median MCV with the different daily doses was not statistically significant \( (P=0.518) \). Similarly, there was no statistically significant difference in mean BMI or age of patients on different doses (Table 3).

Based on duration of metformin intake, patients were again divided into two groups; <4 years and ≥4 years. Patients who had used metformin ≥4 years had significantly lower median vitamin B₁₂ than patients who had used it <4 years \( (P=0.001) \). Furthermore, median serum folate of patients who had used metformin <4 years was significantly higher than patients who had used it ≥4 years \( (P=0.001) \). However, neither MCV \( (P=0.207) \) nor BMI \( (P=0.207) \) was associated with duration of intake (Table 4).

Spearman’s correlation coefficients between variables showed negative correlations between doses \( (r=-0.324^{***}, P=0.003; r=-0.523^{***}, P=0) \) and duration \( (r=-0.313^{***}, P=0.005; r=-0.218^{***}, P=0.052) \) of use with vitamin B₁₂ and folate levels, respectively. MCV values were positively associated with dose and \( (r=0.036^{***}, P=0.752) \) and negatively associated with duration of treatment \( (r=-0.020^{***}, P=0.864) \).

### Discussion

This study was conducted to determine serum vitamin B₁₂ and folate levels and assess macrocytosis in type 2 diabetes mellitus patients on metformin.

Controlled clinical trials of metformin have reported that 7% of patients have subnormal levels of previously normal serum vitamin B₁₂ without clinical manifestations. As well as the package insert for metformin, research has recommended that patients susceptible to low vitamin B₁₂ should have routine serum vitamin B₁₂ blood tests done every 2–3 years in addition to hematological parameters that are recommended on an annual basis. Further, to prevent neurological deterioration rather than treat it once it has begun, it has been suggested that annual monitoring of serum vitamin B₁₂ results in better patient health.

This study indicated an incidence of vitamin B₁₂ levels below the lower reference limit of 5%, and is thus in concordance with other reports. This could be due to interference with vitamin B₁₂ absorption from the B₁₂–IF complex as a consequence of prolonged metformin use or due to nutritional deficiency.

The 23.8% incidence of folate deficiency in patients on higher doses and longer metformin use is in line with other studies. However, comparing the percentage of

<table>
<thead>
<tr>
<th>Duration of metformin intake</th>
<th>&lt;197 pg/mL</th>
<th>≥197 pg/mL</th>
<th>&lt;4.6 ng/mL</th>
<th>≥4.6 ng/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;4 years</td>
<td>0</td>
<td>45 (100)</td>
<td>7 (15.6)</td>
<td>38 (84.40)</td>
</tr>
<tr>
<td>≥4 years</td>
<td>4 (11.4)</td>
<td>31 (88.6)</td>
<td>12 (34.3)</td>
<td>23 (65.7)</td>
</tr>
</tbody>
</table>

| Table 3 Serum Levels of Vitamin B₁₂ and Folate Other Variables Based on daily dose of metformin |
|---------------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Age(years) | <1,000 mg (n=43) | 1,000 mg–1,500 mg (n=16) | >1,500 mg (n=21) | \( P \) |
| BMI (kg/m²) | 55.97±10.86 | 59.5±11 | 54.7±9.7 | 0.476 |
| MCV (fL) | 28.00±25.0297 | 28.27±5.6639 | 26.86±5.7298 | 0.374 |
| Folate (ng/mL) | 7.54 (4.44–20) | 5.56 (4.20–8.55) | 4.55 (2.49–20) | 0.002* |
| Vitamin B₁₂ (pg/mL) | 475.5 (237.6–930) | 297.6 (206–375.6) | 240.4 (135.4–389.3) | <0.001* |

### Table 4 Serum Levels of Vitamin B₁₂ and Folate Other Variables Based on Duration of Metformin Intake

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>&lt;4 Years (n=45)</th>
<th>≥4 Years (n=35)</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI (kg/m²)</td>
<td>56.17±11.17</td>
<td>56.57±9.96</td>
<td>0.873</td>
</tr>
<tr>
<td>MCV (fL)</td>
<td>28.46±5.44</td>
<td>27.2±5.13</td>
<td>0.315</td>
</tr>
<tr>
<td>Folate (ng/mL)</td>
<td>88 (80.1–97.4)</td>
<td>89.1 (80.9–122)</td>
<td>0.207</td>
</tr>
<tr>
<td>Vitamin B₁₂ (pg/mL)</td>
<td>7.54 (3.88–20)</td>
<td>5.95 (2.49–11.85)</td>
<td>0.01*</td>
</tr>
</tbody>
</table>

Note: *Data shown as means ± SD or median (range). \( P<0.05. \)
vitamin B\textsubscript{12} and folate deficiencies of this study with the
prevalence of vitamin B\textsubscript{12} and folate deficiencies in other
studies is not straightforward, and several factors should
be borne in mind. For example, different techniques are
used in determining serum vitamin B\textsubscript{12} and folate levels,
such as high-performance liquid chromatography vs
immunoassay and different cutoff values used for defi-
ciency determination. Furthermore, we did not include
type 2 diabetes mellitus patients without metformin intake
as a control group, which is among factors that have to be
considered when comparing our results and those in the
literature.

Many studies have investigated the effect of dose and
duration of metformin use on vitamin B\textsubscript{12} levels and found
that lower of vitamin B\textsubscript{12} levels are highly prevalent in
patients on higher doses and longer duration of metformin
treatment.\textsuperscript{15,19,23-26} In this study, the smallest value (240
pg/mL) for vitamin B\textsubscript{12} was recorded in patients with type
2 diabetes mellitus with daily intake >1,500 mg. This is
entirely consistent with previous studies, where lower
levels of vitamin B\textsubscript{12} were observed in patients on higher
doses than control groups.\textsuperscript{19,25,27} However, this study is
inconsistent with Nervo et al,\textsuperscript{22} where vitamin B\textsubscript{12} had no
association with the daily dose, but did for duration of use.

In terms of the metformin-treatment duration, as it,
lower levels of vitamin B\textsubscript{12} in patients on prolonged treat-
ment have been reported by a number of studies.\textsuperscript{19,24,26} This
is entirely consistent with this study, with 457.3 pg/mL
vitamin B\textsubscript{12} level observed in patients on metformin <4
years and a significant drop to 263.4 pg/mL in those on
metformin ≥4 years. However, Chen et al\textsuperscript{11} did not find any
significant association between metformin duration and
vitamin B\textsubscript{12} deficiency.

Many studies have already concluded that dose and
duration of metformin treatment are the most important
risk factors of vitamin B\textsubscript{12} deficiency in type 2 diabetes
mellitus patients. For example, in Ko et al, subjects on
metformin >10 years and on >2 g showed about fourfold
the risk of vitamin B\textsubscript{12} deficiency of those with duration
<4 years and on 1 g.\textsuperscript{25} Similarly, each 1 g daily intake
caus ed a near-threefold increase (OR 2.88, \textit{p}=0.001) in
risk of developing vitamin B\textsubscript{12} deficiency. Additionally,
metformin treatment ≥3 years more than doubles (OR
2.39, \textit{p}=0.001) the risk of developing vitamin B\textsubscript{12} defi-
ciency according to Ting et al.\textsuperscript{31} This could explain the
lower levels of vitamin B\textsubscript{12} in our patients on metformin
>4 years and intake >1,500 mg/day than the other group of
patients in our study cohort.

The exact pathogenic mechanisms through which
high doses of metformin and long duration of treatment
cause vitamin B\textsubscript{12} deficiency have not been fully eluci-
dated. However, different proposed mechanisms explain
metformin-induced vitamin B\textsubscript{12} deficiency among
patients with type 2 diabetes mellitus: alterations in
small-bowel motility, which stimulates bacterial over-
growth and consequential vitamin B\textsubscript{12} deficiency, com-
petitive inhibition or inactivation of vitamin B\textsubscript{12}
absorption, alterations in IF levels, and interaction with
the cubulin endocytic receptor, among others.\textsuperscript{6,10}
Metformin has also been shown to inhibit the calcium-
dependent absorption of the vitamin B\textsubscript{12}-IF complex at
the terminal ileum. This inhibitory effect is reversed with
calcium supplementation.\textsuperscript{17}

According to several cohort and case–control studies,
there is a negative causal relationship between dose and
duration of metformin treatment and level of vitamin
B\textsubscript{12}.\textsuperscript{15,23,24,26} This study also revealed a negative cross-
sectional relationship between these variables. However,
due to its design, it was not quite unequivocal about the
direction of causality or relationship, as patients would
have had serum vitamin B\textsubscript{12} lower than normal even
before they had started metformin treatment. Therefore,
future carefully designed research is required to be done
in Ethiopia to ensure the consistency of our findings with
those reported in previous clinical studies.

The folate levels in patients on prolonged and higher dos
of metformin in this study are partly consistent with the
results reported in other studies.\textsuperscript{14,23} It has been reported
that type 2 diabetes mellitus patients with vitamin B\textsubscript{12}
deficiency had folate levels decreased from normal.\textsuperscript{15,23,25}
However, our observations could not confirm that low folate
levels were due to vitamin B\textsubscript{12} deficiency, and how metfor-
min affects folate status has not yet been elucidated.
Deficiency in any form of vitamin B\textsubscript{12} can be due to
different factors, including disease, drug use, and low-vita-
min diet, which can lead to a condition known as folate trap
(functional folate deficiency), where free folate is trapped in
the form of methyltetrahydrofolate.\textsuperscript{20} This could be a pos-
sible reason for type 2 diabetes mellitus patients with vita-
min B\textsubscript{12} deficiency in our study having serum folate levels
below normal. We assessed folate levels in terms of dose
and duration of metformin treatment. However, studies on
levels of serum folate in relation to dose and duration of
metformin treatment are limited and rare. As such, it was
difficult to correlate the results of our study, the first of this
kind in Ethiopia, with those of previous articles.
The percentage of patients with macrocytosis was in agreement with Ko et al., but not with Robert et al who did not find any increase in MCV. Studies investigating the association of metformin-related vitamin B12 deficiency with MCV are rare and varied. However, considering the physiological importance of vitamin B12 and folate in the development of red blood cells, probable reasons for the observed higher MCV values in patients on doses of metformin for prolonged duration could be low serum vitamin B12 and folate levels. Though there were few with macrocytosis, this finding should not be ignored, as both vitamin B12 and folate are required substrates for the maturation of blood cells, and deficiencies in them could lead to a classic form of anemia known as megaloblastic anemia.

In the present study, age did not show any specific pattern as daily dose and was and was insignificantly higher in patients on metformin >4 years. Other studies have shown conflicting results, with some associating age with vitamin B12 deficiency while others finding no relationship. In our study, mean BMI was insignificantly lower in patients on metformin >4 years. In Akinlade et al, patients on metformin for a prolonged duration had mean BMI insignificantly higher than controls. On the other hand, in terms of daily dose, BMI did not show a specific pattern of consistency and was not comparable to findings in previous studies. Therefore, a strong unequivocal relationship connecting age, BMI, and metformin-related vitamin B12 deficiency could not be established.

**Strengths and Limitations**

This first Ethiopian study of this kind has several positive aspects. Firstly, as we assessed the folate levels and macrocytosis in addition to serum vitamin B12 levels, it could serve as a starting point for further investigations. Secondly, it could be used by physicians as a reference to consider the usefulness of monitoring vitamin B12 levels in patients on metformin. This study also has important limitations. Given its cross-sectional design, we were unable to assess time as a factor or hence establish a causal relationship. Age-matched type 2 diabetes mellitus patients not using metformin were not included as a control group. The cohort was also relatively small (80) and there was no age difference among participants. Therefore, to draw clinically significant conclusions, it is recommended that further investigations proceed with larger cohorts, and include biochemical tests for methylmalonic acid and homocysteine levels, considering that these have been identified as better indicators of functional vitamin B12 deficiency than actual serum vitamin B12 level itself.

**Conclusion**

The findings of this study show that low serum vitamin B12 and folate levels were associated with higher doses and a long duration of metformin treatment. Macrocytosis was also observed in patients on prolonged and high-dose metformin use, but with no statistical significance. Therefore, yearly routine monitoring of serum levels of vitamin B12, folate and hematological parameters like MCV and blood film in type 2 diabetes mellitus patients on higher doses and longer duration of metformin treatment are required to monitor the effect of metformin on levels of vitamin B12 and folate and macrocytosis.

**Abbreviations**

BMI, body-mass index; DRERC, Departmental Research and Ethics Review Committee; EPHI, Ethiopian Public Health Institute; IF, intrinsic factor; MCV, mean corpuscular volume.

**Data Sharing Statement**

The data sets used during the current study are available from the corresponding author on reasonable request.

**Author Contributions**

All authors contributed to data analysis, drafting, or revising the article, have agreed on the journal to which the article will be submitted, gave final approval to the version to be published, and agree to be accountable for all aspects of the work.

**Funding**

This work was supported both financially and materially by the Ethiopian Public Health Institution (EPHI) in collaboration with Addis Ababa University.

**Disclosure**

The authors declare that they have no conflicts of interest for this work.

**References**
